798 related articles for article (PubMed ID: 27860216)
1. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
[TBL] [Abstract][Full Text] [Related]
2. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
3. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the sonic hedgehog pathway cause macrocephaly-associated conditions due to crosstalk to the PI3K/AKT/mTOR pathway.
Klein SD; Nguyen DC; Bhakta V; Wong D; Chang VY; Davidson TB; Martinez-Agosto JA
Am J Med Genet A; 2019 Dec; 179(12):2517-2531. PubMed ID: 31639285
[TBL] [Abstract][Full Text] [Related]
6. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
7. Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly
Klein SD; Martinez-Agosto JA
Microrna; 2020; 9(1):70-80. PubMed ID: 31232238
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular data in cases of prenatal localized overgrowth disorder: major implication of genetic variants in PI3K-AKT-mTOR signaling pathway.
Bourgon N; Carmignac V; Sorlin A; Duffourd Y; Philippe C; Thauvin-Robinet C; Guibaud L; Faivre L; Vabres P; Kuentz P;
Ultrasound Obstet Gynecol; 2022 Apr; 59(4):532-542. PubMed ID: 34170046
[TBL] [Abstract][Full Text] [Related]
9. Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
Akgumus G; Chang F; Li MM
J Mol Diagn; 2017 Jul; 19(4):487-497. PubMed ID: 28502730
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders.
Chen J; Alberts I; Li X
Int J Dev Neurosci; 2014 Jun; 35():35-41. PubMed ID: 24662006
[TBL] [Abstract][Full Text] [Related]
11. Vascular malformations syndromes: an update.
Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
[TBL] [Abstract][Full Text] [Related]
12. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Hillmann P; Fabbro D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752127
[TBL] [Abstract][Full Text] [Related]
14. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.
Ocana A; Vera-Badillo F; Al-Mubarak M; Templeton AJ; Corrales-Sanchez V; Diez-Gonzalez L; Cuenca-Lopez MD; Seruga B; Pandiella A; Amir E
PLoS One; 2014; 9(4):e95219. PubMed ID: 24777052
[TBL] [Abstract][Full Text] [Related]
15. Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR.
Dobyns WB; Mirzaa GM
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):582-590. PubMed ID: 31441589
[TBL] [Abstract][Full Text] [Related]
16. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for mosaic overgrowth syndromes of the PI3K-AKT-mTOR pathway.
Morin G; Canaud G
Br Med Bull; 2021 Dec; 140(1):36-49. PubMed ID: 34530449
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
